Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9771413B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 2, 2014 |
| Grant date | Sep 26, 2017 |
| Priority date | — |
| Expiry date | Jan 2, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.